Mineralocorticoid receptor blockade ameliorates peritoneal fibrosis in new rat peritonitis model (Q40000499)

16 September 2017

Mineralocorticoid receptor blockade ameliorates peritoneal fibrosis in new rat peritonitis model (English)

1 reference

sclerosing encapsulating peritonitis

16 September 2017

1 reference

3

Masashi Mizuno

1 reference

16 September 2017

2

Yasuhiko Ito

1 reference

16 September 2017

8

Seiichi Matsuo

1 reference

16 September 2017

6

Shoichi Maruyama

1 reference

16 September 2017

7

Yukio Yuzawa

1 reference

16 September 2017

Hayato Nishimura

1

1 reference

PubMed ID

18353870

16 September 2017

Akio Tanaka

series ordinal

4

1 reference

PubMed ID

18353870

16 September 2017

Yoshiki Morita

series ordinal

5

1 reference

16 September 2017

19 March 2008

1 reference

American Journal of Physiology - Renal Physiology

16 September 2017

1 reference

16 September 2017

294

1 reference

16 September 2017

F1084-93

1 reference

16 September 2017

5

1 reference

Regression of existing glomerulosclerosis by inhibition of aldosterone

16 September 2017

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00565.2007

Role of transforming growth factor beta in human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00565.2007

Transforming growth factor beta in tissue fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00565.2007

Longitudinal relationship between solute transport and ultrafiltration capacity in peritoneal dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00565.2007

Factors influencing peritoneal transport parameters during the first year on peritoneal dialysis: peritonitis is the main factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00565.2007

The transport barrier in intraperitoneal therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00565.2007

Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00565.2007

The nongenomic actions of aldosterone

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00565.2007

Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00565.2007

A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00565.2007

Morphologic changes of peritoneum and expression of VEGF in encapsulated peritoneal sclerosis rat models

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00565.2007

Effect of aldosterone on renal transforming growth factor-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00565.2007

Renoprotective effect of angiotensin-converting enzyme inhibitor combined with alpha1-adrenergic antagonist in spontaneously hypertensive rats with renal ablation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00565.2007

Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00565.2007

Deranged transcriptional regulation of cell-volume-sensitive kinase hSGK in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00565.2007

Plasminogen activator inhibitor-1 deficiency protects against aldosterone-induced glomerular injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00565.2007

Transient overexpression of TGF-{beta}1 induces epithelial mesenchymal transition in the rodent peritoneum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00565.2007

Aldosterone stimulates collagen gene expression and synthesis via activation of ERK1/2 in rat renal fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00565.2007

Mice that lack endothelial nitric oxide synthase are protected against functional and structural modifications induced by acute peritonitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00565.2007

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00565.2007

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00565.2007

Aldosterone antagonism in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00565.2007

Increased expression of mineralocorticoid effector mechanisms in kidney biopsies of patients with heavy proteinuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00565.2007

Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00565.2007

An autopsy study of the peritoneal cavity from patients on continuous ambulatory peritoneal dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00565.2007

Functional longevity of the human peritoneum: how long is continuous peritoneal dialysis possible? Results of a prospective medium long-term study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00565.2007

Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00565.2007

Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00565.2007

SGK1 as a determinant of kidney function and salt intake in response to mineralocorticoid excess

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00565.2007

SGK1-dependent cardiac CTGF formation and fibrosis following DOCA treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00565.2007

The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00565.2007

10.1152/AJPRENAL.00565.2007

21 January 2018

Identifiers

DOI

1 reference

16 September 2017

1 reference

PubMed ID

18353870